№ lp_1_2_37245
File format: docx
Character count: 30679
File size: 215 KB
This PGD outlines the requirements for the administration of RSV vaccine to individuals over 75 and pregnant women from week 28 of pregnancy as part of a national vaccination programme in England.
Year:
2024
Region / city:
England
Subject:
Respiratory Syncytial Virus (RSV) Vaccination
Document type:
Patient Group Direction (PGD)
Organization:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Dr. Mary Ramsay, Greta Hayward
Target audience:
Healthcare practitioners, immunisation services
Valid from:
1 September 2024
Review date:
1 October 2026
Expiry date:
1 April 2027
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Country:
Australia
Region / City:
Victoria, Melbourne
Subject:
Respiratory syncytial virus immunisation during pregnancy
Document type:
Official guidance / fact sheet
Program:
Respiratory Syncytial Virus Mother and Infant Protection Program (RSV-MIPP)
Vaccine name:
Abrysvo® RSV vaccine
Target group:
Pregnant women at 28–36 weeks gestation
Intended users:
Immunisation providers
Dose and route:
Single 0.5 mL dose, intramuscular injection into the deltoid muscle
Co-administration:
Pertussis, influenza and COVID-19 vaccines
Storage conditions:
+2°C to +8°C prior to reconstitution
Issuing authority:
Victorian Government, Department of Health
Publisher address:
1 Treasury Place, Melbourne
Publication date:
January 2025
ISBN:
978-1-76131-797-2
Copyright holder:
State of Victoria, Australia
Year:
2024
Region / City:
Australia
Topic:
Vaccine Approval, Respiratory Syncytial Virus
Document Type:
Clinical Submission
Organization / Institution:
GlaxoSmithKline Australia Pty Ltd
Author:
Unknown
Target Audience:
Health professionals, Policy makers
Effective Period:
Ongoing
Approval Date:
January 14, 2024
Change Date:
April 2024
Year:
2024
Region / city:
Wales
Theme:
Health, Vaccination
Document type:
Patient Group Direction (PGD)
Organization:
Welsh Medicines Advice Service
Author:
Liam Taylor, Dianne Burnett, Hawys Youlden
Target audience:
Registered healthcare professionals
Period of validity:
01 September 2024 – 31 August 2025
Approval date:
18 July 2024
Amendment date:
28 June 2024
Expiry date:
31 August 2025
Year:
2025
Region / City:
Victoria, Australia
Topic:
Immunisation, Respiratory Syncytial Virus (RSV)
Document type:
Consent form, Health guidance
Organization / Institution:
Victorian Government, Department of Health
Author:
Department of Health, Victoria
Target audience:
Parents/guardians of infants, Health professionals
Period of validity:
Ongoing
Date of approval:
April 2025
Date of changes:
Not specified
Year:
2024
Organization:
Department of Veterans Affairs
Office:
Office of Information Technology
Document Type:
Installation Guide
Target Audience:
VA healthcare staff
Clinical Focus:
Respiratory Syncytial Virus Immunization
Components:
Reminder Exchange entry, TIU Template, Health Summary Objects
Population:
Veterans aged 60 and above, pregnant individuals 32–36 weeks gestation
Vaccine Details:
RSV Recombinant Protein Subunit, PF, 0.5 mL
Distribution Method:
Web host file
Installation Duration:
< 20 minutes
Update Number:
2.0.394A
Effective Period:
Seasonal immunization September–January for pregnancy cohort
Year:
2026
Region / City:
Tacoma, WA, USA
Topic:
Communicable diseases in children
Document Type:
Informational letter
Organization:
Tacoma-Pierce County Health Department
Author:
Communicable Disease Division
Target Audience:
Parents and guardians of children
Symptoms:
Cold-like symptoms, bronchiolitis, pneumonia, irritability, poor feeding, lethargy, cyanosis
Transmission:
Close contact with secretions, contaminated surfaces
Prevention Measures:
Hand washing, covering coughs and sneezes, ventilating home, sanitizing surfaces
Exclusion Guidelines:
Children not required to stay home unless too sick
Contact Information:
(253) 798-6410
Type of document:
Official information for health professionals
Topic:
Respiratory syncytial virus vaccination in pregnancy
Vaccine name:
Abrysvo®
Target population:
Pregnant women
Gestational age for administration:
28–36 weeks of pregnancy
Country:
Australia
Health program:
National Immunisation Program
Availability under NIP:
From 3 February 2025
Notifiable disease status:
RSV notifiable in Victoria since 22 February 2022
Regulatory authority:
Therapeutic Goods Administration
Monitoring scheme:
Black Triangle Scheme
Related legislation:
Public Health and Wellbeing Act 2008
Intended audience:
Health professionals
Storage requirements:
+2°C to +8°C
Year:
2025
Country:
Australia
Region / City:
Victoria, Melbourne
Subject:
Respiratory syncytial virus immunisation during pregnancy
Document type:
Official guidance / fact sheet
Program:
Respiratory Syncytial Virus Mother and Infant Protection Program (RSV-MIPP)
Vaccine name:
Abrysvo® RSV vaccine
Target group:
Pregnant women at 28–36 weeks gestation
Intended users:
Immunisation providers
Dose and route:
Single 0.5 mL dose, intramuscular injection into the deltoid muscle
Co-administration:
Pertussis, influenza and COVID-19 vaccines
Storage conditions:
+2°C to +8°C prior to reconstitution
Issuing authority:
Victorian Government, Department of Health
Publisher address:
1 Treasury Place, Melbourne
Publication date:
January 2025
ISBN:
978-1-76131-797-2
Copyright holder:
State of Victoria, Australia
Year:
2025
Region / City:
Victoria, Australia
Topic:
Respiratory Syncytial Virus (RSV) Immunisation
Document Type:
Informational Leaflet
Organ / Institution:
Victorian Government, Department of Health
Author:
Victorian Government
Target Audience:
Parents and carers of infants and young children
Period of Action:
1 April 2025 to 30 September 2025
Approval Date:
February 2025
Date of Changes:
February 2025
Contextual Description:
A government-issued informational leaflet detailing RSV, its risks to infants, and the nirsevimab immunisation, including eligibility, administration, and availability.
Year:
2024
Region / city:
Wales
Theme:
Health, Vaccination
Document type:
Patient Group Direction (PGD)
Organization:
Welsh Medicines Advice Service
Author:
Liam Taylor, Dianne Burnett, Hawys Youlden
Target audience:
Registered healthcare professionals
Period of validity:
01 September 2024 – 31 August 2025
Approval date:
18 July 2024
Amendment date:
28 June 2024
Expiry date:
31 August 2025
Avoiding a Serious RSV Infection and Hospitalization of Your Baby (RSV Season from October 1st 2025)
Country:
Belgium
Topic:
Prevention of RSV infection and bronchiolitis in infants
Document type:
Public health information leaflet
Target audience:
Parents of newborns and infants
Medical focus:
RSV (Respiratory Syncytial Virus) and bronchiolitis
Preventive product:
Nirsevimab (Beyfortus®)
Related vaccine:
Abrysvo®
Institutions mentioned:
Kind&Gezin; ONE in Wallonia
Period concerned:
RSV season (autumn and winter months)
Start date of measure:
October 1st 2025
Reimbursement conditions:
Social insurance with doctor’s prescription; preferential reimbursement available
Administration setting:
Maternity ward or shortly after birth
Geographical scope:
Belgium
Year:
2025
Region / City:
Victoria, Australia
Topic:
Immunisation, Respiratory Syncytial Virus (RSV)
Document type:
Consent form, Health guidance
Organization / Institution:
Victorian Government, Department of Health
Author:
Department of Health, Victoria
Target audience:
Parents/guardians of infants, Health professionals
Period of validity:
Ongoing
Date of approval:
April 2025
Date of changes:
Not specified
Year:
2015
Region / city:
Global
Topic:
Infectious diseases, sepsis, viral and bacterial co-infections
Document type:
Scientific article
Organization / institution:
Various medical institutions and researchers
Author:
Multiple authors
Target audience:
Medical professionals, researchers in infectious diseases
Effective period:
N/A
Approval date:
2015
Modification date:
N/A
Year:
2026
Region / City:
Tacoma, WA, USA
Topic:
Communicable diseases in children
Document Type:
Informational letter
Organization:
Tacoma-Pierce County Health Department
Author:
Communicable Disease Division
Target Audience:
Parents and guardians of children
Symptoms:
Cold-like symptoms, bronchiolitis, pneumonia, irritability, poor feeding, lethargy, cyanosis
Transmission:
Close contact with secretions, contaminated surfaces
Prevention Measures:
Hand washing, covering coughs and sneezes, ventilating home, sanitizing surfaces
Exclusion Guidelines:
Children not required to stay home unless too sick
Contact Information:
(253) 798-6410
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target audience:
Healthcare professionals involved in immunization
Period of validity:
From 5 January 2026 to 5 January 2029
Approval date:
5 January 2026
Amendment date:
2 June 2025, 16 December 2025
Description:
A document detailing the administration guidelines for the pneumococcal polysaccharide conjugate vaccine (PCV13, PCV15) for children under 2 years old in the UK.
Year:
2025
Region / city:
England
Topic:
Influenza immunisation
Document type:
Patient Group Direction (PGD)
Organisation:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Jamie Lopez-Bernal, Greta Hayward
Target audience:
Healthcare practitioners, NHS organisations
Period of validity:
From 1 September 2025 to 1 April 2026
Approval date:
3 July 2025
Revision history:
Updated annually, latest update 9 July 2025
Reference no:
HPV (GBMSM) PGD
Version no:
v5.0
Valid from:
1 September 2025
Review date:
1 April 2028
Expiry date:
1 September 2028
Author:
Suki Hunjunt, Sharif Ismail, David Green
Region / city:
England
Target audience:
Healthcare practitioners administering HPV vaccine to GBMSM
Type of document:
Patient Group Direction
Organisation:
UK Health Security Agency (UKHSA)
Date of approval:
17 July 2025
Date of modifications:
16 July 2025
Context:
A formal Patient Group Direction for the administration of HPV vaccine to GBMSM, detailing legal, clinical, and procedural requirements for healthcare practitioners in England.
Reference no:
Hib/MenC PGD
Version no:
v6.0
Valid from:
1 July 2025
Expiry date:
30 April 2026
Authorising organisations:
UK Health Security Agency (UKHSA)
Target audience:
Registered healthcare practitioners
Responsible body:
UKHSA
Note:
Amendment history
v1.0 and v2.0:
See previous versions of this PGD template for details (19 January 2016 to 23 April 2018)
v3.0:
PHE Hib/MenC PGD amended to: include vaccination of individuals for the prevention of secondary cases of meningococcal group C disease (24 April 2018)
v4.0:
PHE Hib/MenC PGD amended to: remove reference to individuals with an underlying medical condition (5 March 2020)
v5.0:
UKHSA Hib/MenC PGD amended to: include minor rewording of standard text, layout and formatting changes (4 May 2022)
v6.0:
UKHSA Hib/MenC PGD amended to: include minor rewording, updated references, and changes to the childhood immunisation schedule (2 June 2025)
Developed by:
Christina Wilson (Lead Pharmacist), Professor Shamez Ladhani (Paediatric Infectious Diseases Consultant), David Green (Nurse Consultant for Immunisation Programmes)
Peer-reviewed by:
UKHSA Immunisations PGD Expert Panel
Date approved:
2 June 2025
Year:
2025
Region:
England
Subject:
Hepatitis B vaccination for renal patients
Document Type:
Patient Group Direction (PGD)
Authorising Organisation:
UK Health Security Agency (UKHSA)
Target Audience:
Registered healthcare professionals
Period of Validity:
28 February 2025 - 28 February 2028
Approval Date:
28 February 2025
Amendment Date:
21 February 2025
Year:
2024
Region / city:
England
Topic:
Vaccination
Document type:
Patient Group Direction
Organization:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Dr. Mary Ramsay, David Green
Target audience:
Registered healthcare practitioners
Period of validity:
10 October 2024 - 30 April 2027
Approval date:
4 October 2024
Amendments date:
9 October 2024